Dose and context dependent effects of Myc on epidermal stem cell proliferation and differentiation by Berta, Melanie A et al.
Dose and context dependent effects of Myc
on epidermal stem cell proliferation and
differentiation
Melanie A. Berta
1y, Christopher M. Baker
1y, Denny L. Cottle
2y, Fiona M. Watt
1,2*
Keywords: differentiation; Myc;
oncogene; stem cells
DOI 10.1002/emmm.200900047
Received April 1, 2009
Revised August 11, 2009
Accepted September 16, 2009
Myc is activated in many tumours, yet, paradoxically, stimulates differentiation
in mammalian epidermis. To test whether the epidermis responds differently
to different levels of Myc, we treated K14MycER transgenic mice with a range
of concentrations of the inducing agent, 4-hydroxy-tamoxifen (4OHT). Prolifer-
ation was stimulated at all levels of Myc activity; sebocyte differentiation was
stimulated at low and intermediate levels; and interfollicular epidermal differ-
entiation at intermediate and high levels. Mutational inactivation of the Myc p21
activated kinase 2 (PAK2) phosphorylation sites increased Myc activity
and further enhanced epidermal differentiation. We conclude that Myc
induced differentiation acts as a fail-safe device to prevent uncontrolled pro-
liferation and neoplastic conversion of epidermal stem cells expressing high
levels of Myc.
INTRODUCTION
The most common forms of cancer are basal cell carcinoma and
squamous cell carcinoma, non-melanoma tumours of the
epidermis. They are believed to arise when epidermal stem
cells acquire oncogenic lesions that result in uncontrolled
proliferation and impaired differentiation (Janes & Watt, 2006).
The mechanisms that control epidermal stem cell properties are
therefore of considerable interest from the perspectives of
cancer prevention and control.
50% of squamous cell carcinomas arising in patients who
have undergone long-term immunosuppression have v-myc
myelocytomatosis viral oncogene homologue (Myc) ampliﬁca-
tion (Watt et al, 2008). In healthy epidermis, Myc is detected at
low levels in those regions, such as the basal layer of the
interfollicular epidermis (IFE) and bulb of growing hair follicles
(HFs), where proliferation normally occurs (Watt et al, 2008).
Epidermal stem cells tend to divide infrequently (Watt & Jensen,
2009). Myc activation in the epidermis stimulates proliferation,
and maintenance of stem cell quiescence requires expression of
two proteins, B Lymphocyte-induced Maturation Protein-1
(Blimp1) and leucine-rich repeats and immunoglobulin-like
domains 1 (Lrig1), which negatively regulate Myc (Watt et al,
2008; Watt & Jensen, 2009).
Blimp1 is expressed by stem cells in the sebaceous gland (SG)
(Horsley et al, 2006), while Lrig1 is a marker of stem cells in
theIFE(Jensen&Watt,2006;Jensenetal,2009).Overexpression
of Myc in the epidermis not only stimulates proliferation, as in
virtually all cell types (Eilers & Eisenman, 2008), but also,
surprisingly, stimulates differentiation. The lineages that are
expandedonMycactivationarethosethatarenormallycontrolled
by Blimp1 and Lrig1, namely SG and IFE (Arnold & Watt, 2001;
Waikel etal, 2001;Wattetal, 2008). These observationshaveled
to the hypothesis that Myc-induced differentiation is a fail-safe
device to prevent uncontrolled proliferation, and thus tumour
formation, by the epidermal stem cell compartment (Jensen &
Watt, 2006; Jensen et al, 2009; Watt & Jensen, 2009).
In a recent study, cells in a range of adult somatic mouse
tissues were shown to respond differently to different levels of
Myc activation (Murphy et al, 2008). Low levels of Myc were
found to drive proliferation and tumour formation, whereas
high levels triggered the apoptotic Alternative Reading Frame of
Ink4a/CDKN2A locus (ARF)/p53 tumour suppressor pathway.
Although the epidermis is resistant to Myc induced apoptosis,
epidermal terminal differentiation involves loss of proliferative
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characteristics of apoptosis, including activation of transgluta-
minase and caspases (Watt et al, 2008). Thus, the epidermis
mightresponddifferentlytodifferentlevelsofMycactivity,with
differentiation being a selective response to high Myc levels
(Watt et al, 2008).
In order to examine epidermal responsiveness to different
levels of Myc, we used K14MycER transgenic mice (Arnold &
Watt 2001; Frye et al, 2003; Gebhardt et al, 2006; Frye et al,
2007). The keratin14 promoter targets transgene expression to
the basal layer of the IFE, periphery of the SG and outer root
sheath of the HF; transgenes are thus expressed by the known
epidermal stem cell and committed progenitor compartments
(Watt & Jensen, 2009). The C-terminus of the Myc transgene is
fusedtotheligandbindingdomainofamutantestrogenreceptor
(ER); binding of ER by heat shock proteins in the cytoplasm
renders Myc inactive, until on treatment with 4-hydroxy-
tamoxifen (4OHT), the protein translocates to the nucleus and
becomes transcriptionally active (Gandarillas & Watt, 1997).
We previously demonstrated that when a b-cateninER
chimeric protein is expressed in the epidermis, different
levels of b-catenin activity are achieved with different 4OHT
concentrations (Silva-Vargas et al, 2005). We therefore devised
the strategy of using different doses of 4OHT to achieve different
levels of Myc activation in K14MycER mice. This provides a
more reﬁned approach to controlling Myc levels than that of
comparing homozygous and heterozygous transgenic mice
(Murphy et al, 2008).
RESULTS AND DISCUSSION
Differential activation of MycER by different 4OHT
concentrations
We treated keratinocyte lines established from K14MycER
epidermis overnight with 4OHT concentrations ranging from 10
to 200nM, and examined nuclear accumulation of MycER by
immunoﬂuorescence staining with an anti-ER antibody. Pre-
viously, 100nM 4OHT was shown to cause nuclear accumulation
of MycER protein and stimulate differentiation (Gandarillas &
W a t t ,1 9 9 7 ) .I n 90% of MycER cells cultured without 4OHT,
there was no nuclear staining, indicating a low level of transgene
leakiness,asreportedpreviously(Arnold&Watt,2001;Fryeetal,
2003). The proportion of ER-positive nuclei increased approxi-
mately 3.5-fold on addition of 4OHT (up to 35% of cells), with a
peak at 25nM. Higher concentrations of 4OHT did not increase
the proportion of ER-positive nuclei further (Fig 1A, B).
To conﬁrm that there was dose-dependent activation of Myc,
we transfected wild type and K14MycER keratinocytes with a
synthetic Myc reporter (M4) in which luciferase is expressed
under the control of a SV40 promoter enhanced by four Myc
speciﬁc E-boxes, or mM4, a reporter in which the E-boxes have
been mutationally inactivated (Laherty et al, 1997). To control
for transfection efﬁciency, M4 and mM4 were co-transfected
with a Renilla luciferase reporter constitutively expressed under
the control of a cytomegalovirus (CMV) promoter (Fig 1C). Cells
transfectedwithmM4hadlessbasalluciferaseactivitythancells
transfected with M4 (Fig 1D). Wild type cells showed some M4-
dependent luciferase activity, attributable to endogenous Myc,
but this was not affected by 4OHT (Fig 1D). When K14MycER
cells transfected with M4 were treated with 10 or 25nM 4OHT,
luciferase activity increased, maximal activity being observed at
25nM. 200nM 4OHT did not result in any induction relative to
untreated cells (Fig 1D). The bell-shaped dose response
curve was not attributable to changes in total MycER protein
(Fig 1E, F), nor to a decrease in the proportion of cells with
nuclear MycER (Fig 1A, B).
To examine whether different 4OHT concentrations resulted
in different levels of Myc activation in vivo, we treated adult
mouse dorsal epidermis with the following 4OHT doses
dissolved in 100ml acetone: 0.05, 0.1, 0.25, 0.5, 1.0, 1.5
and 3.0mg. Skin was examined 4 days later. Previously we
applied 1mg 4OHT in 200ml ethanol to stimulate differentiation
(Arnold & Watt, 2001; Frye et al, 2003). In K14MycER skin
treated with acetone or WT skin treated with any 4OHT dose, no
nuclear ER labelling was observed (Fig 1G and data not shown).
At the lowest 4OHT dose, 0.05mg, we observed scattered
positive nuclei in the SG (red arrow), bulb of the HF (yellow
arrow) and IFE (white arrow). The number of positively stained
cells in all locations increased progressively with increasing
concentrations of 4OHT (Fig 1G and data not shown).
To examine whether there was a dose-dependent change
inexpressionofMyctargetgenes,westainedepidermalsections
with antibodies to nucleolin and thea6 integrin subunit (Fig 1H, I).
Nucleolin expression is positively regulated by Myc, whereas a6
integrin expression is repressed (Frye et al, 2003; Gebhardt et al,
2006). The number of nucleolin positive cells increased with
increasing 4OHT dose (Fig 1H). a6 staining was unaffected by
low concentrations of 4OHT, but was reduced and discontin-
uous at the highest concentration, 3mg (Fig 1I, asterisk).
We conclude that, both in culture and in vivo, different levels
of Myc activity in K14MycER expressing keratinocytes can be
achieved by varying the 4OHT concentration to which the cells
are exposed.
Different levels of Myc activity differentially affect epidermal
proliferation and differentiation
There was no discernable effect of 4OHT on wild type skin, nor
of acetone on K14MycER skin (Fig 2A, data not shown; Arnold &
Watt, 2001; Frye et al, 2003). However, the consequences of
Myc activation in K14MycER skin differed according to the dose
of 4OHT applied (Fig 2B–D).
Ki67labellingwasusedtoevaluateproliferation(Fig 2E–I).In
wild type telogen epidermis and untreated K14MycER epidermis
there were small numbers of positive cells in the IFE basal layer
and periphery of the SG (Fig 2E, I and data not shown). At all
doses of 4OHT, the IFE basal layer became highly proliferative
(Fig 2F–I and data not shown), while proliferation in the SG and
HF increased with increasing dose (Fig 2G, H). At all 4OHT
doses, IFEproliferation waslargelyconﬁned tothe basallayerof
transgene positive cells (Fig 2F–H).
Low 4OHT doses led to no (0.05mg) or a small (0.1mg)
increase in IFE thickness, whereas medium and high doses
triggered marked thickening (Fig 2B–D, F–H, J). The thickening
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Figure 1. 4OHT dose-dependent induction of Myc.
Transgene-negative (WT) and K14MycER (Myc) keratinocytes and mice were treated with the 4OHT concentrations (nM) or doses (mg) indicated.
A. Anti-ER staining of immortalized K14MycER and WT keratinocytes. Yellow arrowhead: negative nucleus, white arrowhead: positive nucleus.
B. Fold change in ER-positive nuclei relative to untreated K14MycER cells. Data are mean SEM of three independent experiments. Asterisks: p<0.05.
C. Constructs used in luciferase assays.
D. Cells were transfected with the constructs indicated. Firefly luciferase was normalized against R. luciferase activity. Relative light units (RLUs) are shown.
Mean SEM of six experiments performed in duplicate. Asterisks: p<0.05 relative to WT cells transfected with M4 treated with same 4OHT concentration.
E. Western blot probed with anti-ER or, as loading control, a-tubulin (tub) antibody.
F. Quantitation of ER protein by densitometry, showing mean SEM of at least three blots.
G–I. Dorsal skin of WT and K14MycER mice treated with 4OHT doses indicated, stained with antibodies to ER (G), nucleolin (H) or a6 integrin (I). White arrow:
positive IFE cells; red arrow: positive SG cells; yellow arrow: positive HF bulb cells. Asterisk in (I): focal loss of a6. Scale bars: 10mm (A, G-H, I, 0.05mg), 50mm
(I, other doses).
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tiating cell layers rather than expansion of the basal compart-
ment (Fig 2A–H and data not shown).
SGs have an outer layer of undifferentiated, proliferative
cells. As cells move towards the centre of the gland, they
undergo terminal differentiation and are identiﬁed by their large
size and pale cytoplasm (Lo Celso et al, 2008). In back skin the
long axis of a normal SG is parallel to its associated HF (Fig 2A).
We have previously reported that on Myc activation, the SG
becomes greatly enlarged and expands into the adjacent HF,
occupying the region below the infundibulum and above the
base of the HF (Arnold & Watt, 2001; Frye et al, 2003). By
measuring the maximum width and length of SG from
micrographs, we determined that there was a variable, 3–10-
fold increase in total SG area at 4OHT concentrations of 0.05 to
3mg (Fig 2B–D and data not shown).
WhiletheSGwasenlargedatall4OHTconcentrations,different
4OHT concentrations differentially inﬂuenced the number of
differentiated cells that expressed fatty acid synthase (FAS)
(Fig 2K–N) and fatty acid binding protein 5 (FABP5) (Fig 2Q–S)
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Figure 2. Epidermal response to different Myc levels. K14MycER and transgene negative (WT) dorsal skin was treated with the 4OHT doses indicated.
A–D. Haematoxylin and eosin (H&E) staining. Doubleheaded arrows: SG enlargement (B); IFE thickening (C).
E–H. Ki67 immunostaining.
I. % Ki67 positive cells SEM in IFE basal layer.
J. Maximum IFE thickness (mm) SEM.
K–N, Q–S. Immunofluorescence stainingfor FAS(green, K–N) withDAPI nuclear counterstain (blue,K–N)or FABP5 (Q–S).Arrows indicate FAS expression. Brackets
demarcate SG.
O,P. H&E staining of IFE. Arrows show ectopic sebocytes. Scale bars: 10mm (A–H, K–P), 75mm (Q–S).
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increased at low 4OHT doses (Fig 2K, L) but FAS was almost
undetectable at the highest doses (Fig 2M, N). There was also an
expansionofFABP5expressionatlow4OHTdoses(Fig2Q,R)and
a reduction at higher doses (Fig 2S). The appearance of rare
differentiated sebocytes in the IFE (Arnold & Watt, 2001; Braun
et al, 2003) was stimulated at all 4OHT concentrations (Fig 2O, P
and data not shown), suggesting that the loss of differentiated
sebocytes in the SG at high 40HT concentrations reﬂected an
expansion of the undifferentiated sebocyte compartment rather
than a block in sebocyte terminal differentiation.
Weconcludethatdifferent levels ofMyc activityhavedifferent
effects on epidermal proliferation and differentiation. Prolifera-
tion is stimulated at all levels. Low doses stimulate sebocyte
terminal differentiation while at high doses the undifferentiated
cells of the SG expand. IFE differentiation is unaffected at low
4OHT doses, but is stimulated at doses of 0.1mg and above.
Mutation of the PAK2 phosphorylation sites enhances Myc
activity
Myc activity is regulated by Myc binding partners and post-
translational modiﬁcations (Eilers & Eisenman, 2008). p21
activated kinase 2 (PAK2)-mediated phosphorylation of Myc on
three C-terminal residues (T358, S373 and T400), reduces the
afﬁnity of Myc for MYC associated factor X (Max), decreases the
DNA binding afﬁnity of Myc/Max heterodimers and decreases
Mycstability (Huang,2004;Huangetal,2004). PAK2 isactivein
the epidermal stem cell compartment and acts downstream of
ras-related C3 botulinum toxin substrate (Rac1) to negatively
regulate Myc induced differentiation (Benitah et al, 2005;
Watt et al, 2008). We tested whether mutational inactivation of
the Myc PAK2 phosphorylation sites increased Myc-induced
differentiation by generating K14MycAER transgenic mice in
which the three Myc residues targeted by PAK2 were replaced
by alanines. The level of transgene-encoded Myc protein was
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Figure 3. Mutation of PAK2 phosphorylation sites enhances Myc activity. WT: transgene-negative; Myc: K14MycER; MycA: K14MycAER.
A. Western blotof dorsalskin lysates probedwithanti-ER.Equalprotein loading was verifiedbyPonceau staining(P).Secondlanefromleft:molecular mass markers.
B. Luciferase assays performed as in Fig 1C, D.
  p<0.01,
   p<0.005 relative to WT cells transfected with M4 treated with same 4OHT concentration.
C. Q-PCR of nucleolin mRNA.
 p<0.05,
   p<0.005 relative to WT cells at same 4OHT concentration.
D. Western blotting of PAK2 and a-tubulin (a-tub; loading control) in cells transfected with PAK2 or control (neg) siRNAs. Densitometric analysis of three
blots SEM is shown. Asterisks:
 p<0.05 relative to neg cells.
E. Q-PCR of PAK2 mRNA levels in cells transfected with control (neg) or PAK2 siRNA.
   p<0.005 relative to negative control siRNA transfected cells, treated with
the same 4OHT concentration.
F. FoldincreaseinnucleolinexpressionincellstransfectedwithPAK2siRNArelativetocontrolsiRNA.
 p<0.05,
  p<0.01relativeto0nM4OHTtreatedcells.(C,E,F)
GAPDH was used for normalization. (B, C, E, F) Data are mean SEM from 5 (B, E, F) or 4 (C) experiments.
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examined (Fig 3A).
Cultured keratinocyte lines established from K14MycAER
mice were transfected with the luciferase reporters shown in
Fig 1C and treated with different concentrations of 4OHT.
Maximal stimulation of luciferase activity was observed at
10nM4OHT andwas sustained atall dosestested (Fig 3B).Thus
maximal activity was achieved at a lower 4OHT concentration
than in K14MycER cells and there was no tailing off of activity at
200nM (cf Fig 1D, Fig 3B).
Toconﬁrm thatMycAERwasmoreeffectiveinactivatingMyc
target genes, we used quantitative PCR to measure nucleolin
mRNA levels (Fig 3C). Nucleolin was induced in a dose-
dependent manner in MycER and MycAER cells, but mRNA
levelswerehigher in MycAERcellsatboth4OHT concentrations
tested (Fig 3C).
To examine whether the enhanced transcriptional activity
of MycA was attributable to insensitivity to PAK2, we
transfected K14MycER and K14MycAER keratinocytes with a
short interfering RNA (siRNA) targeting PAK2 or a control
siRNA (neg). Western blotting revealed a 40–60% reduction in
PAK2 protein (Fig 3D). A 70% reduction in PAK2 mRNA levels
was detected by Q-PCR in K14MycER and a 60% reduction in
K14MycAER cells, both in the presence and absence of 4OHT
(Fig 3E).
Myc-induced upregulation of nucleolin was not observed in
K14MycER cells transfected with negative control siRNA,
possibly reﬂecting stress-induced PAK2 activation (data not
shown). However, when PAK2 was knocked down, MycER-
induced activation of nucleolin was restored (Fig 3F).
K14MycAER cells were insensitive to PAK2 inhibition, and
upregulated nucleolin to the same extent as non-transfected
cells in the presence of control or PAK2 siRNA (Fig 3F).
Mutation of the PAK2 phosphorylation enhances Myc induced
differentiation in culture
To test whether MycA was more potent than wild type Myc in
inducing keratinocyte differentiation in culture, we examined
the colony forming efﬁciency (CFE) of K14MycER and
K14MycAER keratinocytes treated with 4OHT for 8–12 days
(Fig 4A). The CFE of K14MycER keratinocytes increased slightly
in20nM4OHTbutat2and200nMwasthesameasinuntreated
cells. In contrast, the CFE of K14MycAER cells was dramatically
reduced by 4OHT concentrations of 20nM and above (Fig 4A).
We also compared the area of the largest colonies formed by
K14MycER and K14MycAER keratinocytes in the presence of 0
or 200nM 4OHT. Colony size was not affected by Myc
activation, but was markedly reduced on activation of MycA
(Fig 4C, D).
As a further readout of Myc induced differentiation, we
examined integrin-mediated adhesion (Frye et al, 2003;
Gebhardt et al, 2006). a6 integrin mRNA levels were unchanged
when K14MycER cells were treated for 16h with 4OHT
(Fig 4B). In contrast, a6 integrin mRNA was downregulated
in K14MycAER cells (Fig 4B). Consistent with this, K14MycAER
cells exhibited reduced cell-substrate adhesion in response to
4OHT, whereas K14MycER cells did not (Fig 4E).
PAK2 insensitive mutant Myc enhances epidermal
differentiation
We next examined the response of K14MycAER mice to the
4OHT doses tested on K14MycER mice. Like K14MycER mice,
K14MycAER mice exhibited increased proliferation, IFE thick-
ening and SG enlargement (Fig 5A–J). Proliferation was sti-
mulated at all 4OHT doses and, in the IFE, was largely conﬁned
tothebasallayer(Fig5E–G).However,IFEthickeningwasmore
pronounced at a low 4OHT dose (0.1mg 4OHT) in K14MycAER
than K14MycER mice (Fig 5H). Focal loss of a6 integrin
expressionwasobservedinK14MycAERmice(datanotshown),
consistent with the Q-PCR data from cultured keratinocytes
(Fig 4B).
Activation of MycA increased the proportion of cells in the
later stages of IFE terminal differentiation to a greater extent
than Myc, an effect that was particularly pronounced at 8 days
(Fig 5I). This is the longest time for which K14MycAER mice
could be treated, because the epidermis became overtly fragile
and ﬂaky, and mice exhibited weight loss and dehydration. At
8 days the granular layer was expanded in K14MycAER mice
and the granular cells failed to ﬂatten (Fig 5I). This is remini-
scent of the effects of overexpressing active coﬁlin in reconsi-
tuted human epidermis, supporting the model that LIM domain
kinase (LIMK)-mediated downregulation of Myc plays a role in
granular layer compaction (Honma et al, 2006). In K14MycAER
mice, the combined granular and corniﬁed layers constituted
62% of IFE thickness, compared to 40% in K14MycER mice.
Whereas Myc and MycA activation were equally effective in
enlarging the SG, in K14MycAER skin terminally differentiated
sebocytes were preserved at the highest 4OHT concentrations
(Fig 5J). This was quantitated by measuring the area of
individual SG that stained positive for FABP5 (Fig 5J, K). In
K14MycER mice the FABP5 positive areas increased at 0.05
and 0.1mg 4OHT, then decreased at higher doses (also see
Fig 2Q–S). In contrast, FABP5 labelling in K14MycAER skin was
further enhanced by 1.5mg compared to 0.5mg 4OHT (Fig 5K).
Rare IFE sebocytes were seen at all 4OHT concentrations in
K14MycAER skin, as in K14MycER skin (data not shown).
Weconcludethatepidermalkeratinocytesresponddifferently
to different levels of Myc activation (Fig 5L). Proliferation was
stimulated at all levels, whereas there was progressive accumu-
lation of differentiated cell layers in the IFE with increasing
4OHT concentration. In K14MycER mice accumulation of
differentiated sebocytes within the SG was greater at low and
intermediate 4OHT doses than at high doses. In contrast,
activation of MycAER preserved SG differentiation even at high
4OHT doses. The phenotype of K14MycAER mice suggests that
PAK2 mediated phosphorylation serves as a negative regulator
ofMycinduceddifferentiationbutnotproliferation,highlighting
the importance of the Rac1/PAK2/Myc axis in regulating
epidermal differentiation (Benitah et al, 2005; Watt et al, 2008).
Our observations support the hypothesis that Myc-induced
IFE differentiation is a fail-safe mechanism to prevent uncon-
trolled proliferation of the stem cell compartment (Jensen &
Watt, 2006; Watt et al, 2008). Low levels of Myc stimulate
proliferation and enable stem cell expansion, while high levels
trigger accumulation of terminally differentiated cells and
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carcinoma. Our results support the conclusion that in somatic
tissues Myc must be activated at a low level to avoid engaging
tumour suppression mechanisms: apoptosis in the case of
tissues such as pancreas (Murphy et al, 2008) and terminal
differentiation in the epidermis. Our studies also raise the
intriguing possibility that in squamous cell carcinomas with
Myc ampliﬁcation, the oncogene may not only be driving
proliferation but also stimulating some cells to undergo
differentiation.
MATERIALS AND METHODS
An expanded version of Materials and Methods can be found under
Supporting Information
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Figure 4. Differential responses of cultured keratinocytes to activation of Myc and MycA.
A. Mean fold change in CFE SEM in keratinocytes cultured for 8 days in the presence or absence of 4OHT. Data pooled from triplicate dishes in three
independent experiments.
 p<0.05 relative to Myc expressing cells treated with same 4OHT concentration.
B. Q-PCR of a6 integrin mRNA normalized to GAPDH. Data are mean SEM of three experiments.
 p<0.05,
  p<0.01 relative to WT treated with same 4OHT
concentration.
C. Size of largest colonies after 8 days in 0 or 200nM 4OHT. At least 21 colonies from triplicate dishes are shown. Red bars: median values.
   p<0.005.
D. Dishes of keratinocytes in CFE experiments, fixed after 8 (Myc) or 12 (MycA) days.
E. Phase contrast micrographs of keratinocytes in unsupplemented Keratinocyte Serum Free Medium (KSFM) treated with 4OHT for 24h. Scale bars: 10mm.
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Figure 5. Epidermal response to MycA.WT: transgene negative; Myc: K14MycER; MycA: K14MycAER. 4OHT doses are indicated.
A–D. H&E stained sections of back skin. Arrowhead in (B) shows IFE thickening. Arrows (B–D): differentiated sebocytes.
E,F. Ki67 labelling of back skin. Arrows: SG.
G. % Ki67 positive IFE basal layer cells SEM.
H. Maximum IFE thickness (mm) SEM.
I. IFE basal (BL), spinous (SL), granular (GL) and cornified (CL) layers; 8 days, 0.5mg 4OHT.
J. FABP5 staining. Bracket: SG.
K. Scatterplot of FABP5 positive area of individual SG; at least 28 SGs per condition. Red bar: median.
 p<0.05,
   p<0.005.
L. Summary of effects of Myc and MycA on proliferation of undifferentiated keratinocytes (UD) and differentiation into SG and IFE. Thickened arrows indicate
stimulation relative to control, untreated epidermis. Scale bars: 10mm (A–F), 50mm (I), 75mm (J).
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K14MycER transgenic mouse founder line 2184C.1 (Arnold & Watt,
2001) and K14MycAER founder line 6972.C3 were used. Mice were
treated once with the stated doses of 4OHT dissolved in 100ml
acetone and harvested 4 days later, except when stated. All experi-
ments were subject to Cancer Research (CR)-UK ethical review and
performed under the terms of a UK Government Home Office licence.
Keratinocyte culture
Primary and spontaneously immortalized keratinocytes were cultured
essentially as described previously (Silva-Vargas et al, 2005). To
determine CFE, 10
3 keratinocytes (passage 7–10), were seeded per
well in triplicate wells of 6-well plates. To examine Myc-induced cell
rounding, 4 10
5 cells were seeded per well in 6 well plates (Silva-
Vargas et al, 2005) overnight without feeders. The cells were trans-
ferred to complete Keratinocyte Serum Free Medium (KSFM) for 24h
and then to unsupplemented KSFM 4OHT for an additional 24h.
siRNA transfection
4 10
5 cells were seeded per well in 6 well plates overnight. Adherent
keratinocytes were transfected with 2mlo f2 0 mM siRNA and 2ml
lipofectamine 2000 in unsupplemented KSFM for 4h, then cultured in
complete KSFM for 2 days before harvesting. Qiagen All stars negative
control siRNA 1027280 and Qiagen Mm_Pak2_1 HP siRNA
SI01368647 siRNA oligos were used.
Q-PCR
Keratinocytes were either starved for 16h in unsupplemented KSFM
and then transferred to unsupplemented KSFM 4OHT for 5h or
treated with unsupplemented KSFM 4OHT for 16h without prior
starvation. Quantitative PCR was performed as described (Frye et al,
2003).
Immunohistochemistry
Antibodies against the following proteins were used: FAS (IBL), c-myc
(N-262 sc-764, Santa Cruz), ERa (MC-20 sc-542, Santa Cruz), a6
integrin (GoH3, Serotec), Nucleolin (A300-711A, Bethyl Laboratories),
PAK2 (A301-263A, Bethyl Laboratories), actin (AC-40, Sigma), Ki67
(Neomarkers, Fremont, CA), FABP5 (BAF1476, R&D Systems). Alexa-
Fluor 488- or 555-conjugated goat anti-rabbit, anti-mouse or anti-rat
IgG (Invitrogen Corporation; Paisley, UK) were used to detect primary
antibodies. Slides were mounted in Slow Fade Gold reagent
(Invitrogen).
Tissue samples were either fixed overnight in neutral buffered
formalin or 4% PFA and embedded in paraffin or else frozen, unfixed,
in OCTcompound (Miles). Cultured keratinocytes were fixed in 4% PFA
and stained with 40-6-diamidino-2-phenylindole (DAPI) and anti-ER.
Slides were viewed on a Olympus DMI6000 or Nikon confocal
scanning microscope.
Quantitation of Ki67 labelling, IFE thickness and SG differentiation
was performed as described in the Supporting Information.
Western blotting
Proteins were extracted from whole skin in radioimmunoprecipitation
(RIPA) buffer containing a protease inhibitor cocktail (Roche) using a
homogenizer (Power Gen 500, Fisher Scientific). Proteins were
extracted from cultured keratinocytes by scraping into ice cold (4-
(2-hydroxyethyl)-1-piperazineethanesulphonic acid) (HEPES) lysis
buffer (10mM HEPES pH 8, 10mM KCl, 0.1mM ethylenediaminete-
traacetic acid (EDTA), 0.2% NP-40, Roche protease inhibitor cocktail).
Proteins were resolved by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene fluoride (PVDF, NEN) or nitrocellulose
(Amersham) membranes essentially as described previously (Arnold &
Watt, 2001; Silva-Vargas et al, 2005).
Luciferase assays
Keratinocytes were seeded without feeders in 48-well collagen-coated
plates at a density of 2.5 10
4 cells per well and allowed to adhere
overnight. Adherent keratinocytes were transfected with 1ml lipofec-
tamine 2000, mixed with 1.15mg of pGL2-M4 or pGL2-mutantM4
firefly luciferase reporter plasmids (kindly provided by Robert
Eisenman; Laherty et al 1997) and 0.1mg pCMV-RL R. luciferase
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PROBLEM:
Myc is a classic oncogene that is frequentlyupregulated in a wide
variety oftumours.It is therefore surprisingthat inthe epidermis,
high levels of Myc promote differentiation rather than tumour
formation. We set out to test the hypothesis that the epidermal
response to Myc is dependent on the level of Myc activity.
RESULTS:
We were able to modulate Myc activity in a transgenic mouse
model by using different doses of the transgene-inducing agent,
4-hydroxy-tamoxifen (4OHT).
We found that low levels of Myc activity stimulated proliferation
while higher levels stimulated differentiation into sebaceous
glands and interfollicular epidermis. By preventing negative
regulation of Myc via Pak2 phosphorylation, we achieved a more
potent stimulation of epidermal differentiation.
IMPACT:
Many epithelial tumours contain areas of proliferation and areas
of differentiation, and the degree of differentiation is used as a
predictor of prognosis. Our studies raise the intriguing possibility
that in tumours with Myc amplification, the oncogene is not only
driving proliferation but also stimulating differentiation.
24  2009 EMBO Molecular Medicine EMBO Mol Med 2, 16–25 www.embomolmed.orgreporter in unsupplemented KSFM medium for 4 hours. Keratinocytes
were incubated in complete KSFM overnight, then transferred to
unsupplemented KSFM containing 0–200nM 4OHT in ethanol for
24h. Keratinocytes lysates were assayed using the Promega dual
luciferase reporter assay kit according to the manufacturer’s instruc-
tions and analysed on a Glomax luminometer (Promega). Luciferase
values were normalized to R. luciferase activity to adjust for
transfection efficiency.
Statistics
Statistical analysis was performed using the unpaired Student’s t-test.
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